XML 78 R30.htm IDEA: XBRL DOCUMENT v3.25.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenues Recognized under Agreement
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
20242023
Revenue related to Genentech agreement:
Recognition of license revenue$48,679 $— 
Research services1,321 — 
Total$50,000 $— 
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
20242023
Revenue related to Kite agreement:
Recognition of license fee fixed consideration$— $19,423 
Research services variable consideration— 1,097 
Total$— $20,520 
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
20242023
Revenue related to Novartis agreement:
Recognition of upfront license fee$— $9,568 
Research services— 2,611 
Total$— $12,179 
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
20242023
Revenue related to Biogen agreement:
Recognition of license and other fixed consideration$— $132,165 
Cost-sharing payments for research services, net variable consideration— 2,684 
Total$— $134,849